^
BIOMARKER:

MET exon 14 mutation

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
PharmaTimes - 1 week
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
crizotinib
Sensitive: A2 - Guideline
MET exon 14 mutation
LUAD
tepotinib
Sensitive: C1 - Off-label
MET exon 14 mutation
NSCLC
APL-101
Sensitive: C2 – Inclusion Criteria
MET exon 14 mutation
NSCLC
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
MET exon 14 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
MET exon 14 mutation
NSCLC
c-MET inhibitor
Sensitive: C3 – Early Trials
MET exon 14 mutation
NSCLC
nivolumab
Sensitive: C3 – Early Trials
MET exon 14 mutation
Biliary Tract Cancer
c-MET inhibitor
Sensitive: C3 – Early Trials
MET exon 14 mutation
NSCLC
c-MET inhibitor + Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
MET exon 14 mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
MET exon 14 mutation
NSCLC
pembrolizumab
Sensitive: C4 – Case Studies
MET exon 14 mutation
LUAD
crizotinib
Sensitive: C4 – Case Studies
MET exon 14 mutation
LUAD
cabozantinib tablet
Sensitive: C4 – Case Studies
MET exon 14 mutation
Gastric Cancer
Sym015
Sensitive: D – Preclinical